Portland Global Advisors LLC lowered its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 1.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 35,915 shares of the company’s stock after selling 385 shares during the period. Portland Global Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $1,804,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Lazard Asset Management LLC raised its position in shares of Teva Pharmaceutical Industries by 1.9% in the first quarter. Lazard Asset Management LLC now owns 12,949,435 shares of the company’s stock valued at $692,923,000 after buying an additional 240,228 shares in the last quarter. Institutional Capital LLC increased its position in shares of Teva Pharmaceutical Industries by 4.2% in the first quarter. Institutional Capital LLC now owns 5,310,234 shares of the company’s stock valued at $284,151,000 after buying an additional 212,242 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Teva Pharmaceutical Industries by 7.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 4,482,801 shares of the company’s stock valued at $239,875,000 after buying an additional 292,860 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Teva Pharmaceutical Industries by 26.1% in the first quarter. UBS Asset Management Americas Inc. now owns 3,015,673 shares of the company’s stock valued at $161,368,000 after buying an additional 624,629 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Teva Pharmaceutical Industries by 51.4% in the first quarter. TIAA CREF Investment Management LLC now owns 2,485,296 shares of the company’s stock valued at $132,988,000 after buying an additional 843,358 shares during the last quarter.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up 1.49% during trading on Thursday, hitting $51.23. The stock had a trading volume of 2,969,972 shares. The company has a market cap of $46.82 billion, a PE ratio of 34.22 and a beta of 0.82. The company’s 50 day moving average is $52.18 and its 200-day moving average is $53.27. Teva Pharmaceutical Industries Ltd has a 12 month low of $48.01 and a 12 month high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, topping the consensus estimate of $1.20 by $0.05. The company had revenue of $5 billion for the quarter, compared to analyst estimates of $4.86 billion. The firm’s revenue was up 1.4% on a year-over-year basis. During the same period last year, the business earned $1.43 earnings per share. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd will post $5.26 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Monday, August 22nd were issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 2.65%. The ex-dividend date of this dividend was Thursday, August 18th.

Several equities analysts have recently weighed in on TEVA shares. Mizuho restated a “buy” rating and set a $64.00 price target (down from $70.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, August 25th. Oppenheimer Holdings Inc. set a $66.00 price target on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, September 12th. Leerink Swann set a $61.00 price objective on Teva Pharmaceutical Industries and gave the stock an “outperform” rating in a report on Wednesday, August 31st. Credit Suisse Group AG reiterated a “neutral” rating and issued a $51.63 price objective (down from $59.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, August 25th. Finally, Vetr upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $60.02 price objective for the company in a report on Monday, August 1st. Seven analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $67.54.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.